LUX-Lung 3: Redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer

Future Oncology

Volumn 10, Issue 4, 2014, Pages 533-540

  Köhler, Jens ^a   Schuler, Martin ^a,b,c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

afatinib; EGFR mutated lung cancer; first line; irreversible EGFR TKI; LUX Lung 3; side effects

Indexed keywords

AFATINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DIARRHEA; DRUG SAFETY; DRY SKIN; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; GERMLINE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG TOXICITY; METASTASIS; METASTATIC LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARONYCHIA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECEPTOR GENE; REVIEW; SEPSIS; STOMATITIS; STUDY DESIGN; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; FEMALE; GENETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84899471615     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.9     Document Type: Review

References (41)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004
2. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004
3. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): A multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012
4. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735-742 (2011
5. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010
6. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010
7. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008
8. Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19(8), 2240-2247 (2013
9. Yun CH, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105(6), 2070-2075 (2008
10. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011
11. Mink SR, Vashistha S, Zhang W, Hodge A, Agus DB, Jain A. Cancer-Associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol. Cancer Res. 8(6), 809-820 (2010
12. Yano S, Wang W, Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-Activating mutations. Cancer Res. 68(22), 9479-9487 (2008
13. Su KY, Chen HY, Li KC et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30(4), 433-440 (2012
14. Bell DW, Gore I, Okimoto RA et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 37(12), 1315-1316 (2005
15. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343(2), 342-350 (2012
16. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702-4711 (2008
17. Murakami H, Tamura T, Takahashi T et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/ erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother. Pharmacol. 69(4), 891-899 (2012
18. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A Phase 2b/3 randomised trial. Lancet Oncol. 13(5), 528-538 (2012
19. Yang JC, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A Phase 2 trial. Lancet Oncol. 13(5), 539-548 (2012
20. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327-3334 (2013
21. UICC International Union Against Cancer. TNM Classification of Malignant Tumours (6th Edition). Wiley-Liss, NY, USA (2002
22. Eisenhauer EA,, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009
23. Yang JC, Hirsh V, Schuler M et al. Symptom control and quality of life in LUX-Lung 3: A Phase III study of afatinib or cisplatin/ pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3342-3350 (2013
24. Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: Clinical experience and management. Clin. Lung Cancer 4(6), 366-369 (2003
25. Engelman JA, Zejnullahu K, Gale CM et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67(24), 11924-11932 (2007
26. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009
27. Wu YL, Zhou C, Hu CP et al. LUX-Lung 6: A randomized, open-label, Phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J. Clin. Oncol. 31(Suppl.), Abstract 8016 (2013
28. Lacouture ME, Schadendorf D, Chu CY et al. Dermatologic adverse events associated with afatinib: An oral ErbB family blocker. Expert Rev. Anticancer Ther. 13(6), 721-728 (2013
29. Yang JC, Reguart N, Barinoff J et al. Diarrhea associated with afatinib: An oral ErbB family blocker. Expert Rev. Anticancer Ther. 13(6), 729-736 (2013
30. Yang JC, Sequist LV, Geater SL et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three trials of afatinib in EGFR mutation-positive lung cancer. 15th World Conference on Lung Cancer 2013, Sydney, Australia, 27-31 October 2013, Abstract 03.02 (2013
31. LUX-Lung 7: A Phase IIb trial of afatinib(BIBW2992) versus gefitinib for the treatment of 1st line EGFR mutation positive adenocarcinoma of the lung. http://clinicaltrials.gov/show/NCT01466660
32. LUX-Lung 8: A Phase III trial of afatinib (BIBW 2992) versus erlotinib for the treatment of squamous cell lung cancer after at least one prior platinum based chemotherapy. http://clinicaltrials.gov/show/NCT01523587
33. Katakami N, Atagi S, Goto K et al. LUX-Lung 4: A Phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 31(27), 3335-3341 (2013
34. Schuler MH, Planchard D, Yang JCH et al. Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy. J. Clin. Oncol. 30(Suppl.), Abstract 7557 (2012
35. Kim JH, Grossi F, De Marinis F et al. Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial. J. Clin. Oncol. 30(Suppl.), Abstract 7558 (2012
36. Godin-Heymann N, Ulkus L, Brannigan BW et al. The T790M 'gatekeeper' mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 7(4), 874-879 (2008
37. Janjigian YY, Azzoli CG, Krug LM et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin. Cancer Res. 17(8), 2521-2527 (2011
38. Regales L, Gong Y, Shen R et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 119(10), 3000-3010 (2009
39. Janjigian Y, Groen H, Horn L et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J. Clin. Oncol. 29(Suppl.), Abstract 7525 (2011
40. Ranson M, Pao W, Kim DW et al. Preliminary results from a Phase I study with AZD9291: An irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations in non-small-cell lung cancer (NSCLC). European Cancer Congress 2013, Amsterdam, The Netherlands, 27 September-1 October 2013, Abstract 33 (2013
41. Sequist LV, Soria JC, Gadgeel SM et al. First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. J. Clin. Oncol. 31(Suppl.), Abstract 2524 (2013